RF ablation 'biopsy' shows prognostic potential

Article

The histopathology of residual tissue from radiofrequency ablation probes after ablation of hepatocellular carcinomas could predict local tumor progression independently from other tests, according to a study presented at the 2007 Society of Interventional Radiology meeting.

The histopathology of residual tissue from radiofrequency ablation probes after ablation of hepatocellular carcinomas could predict local tumor progression independently from other tests, according to a study presented at the 2007 Society of Interventional Radiology meeting.

Dr. Constantinos T. Sofocleous, an interventional radiologist at Memorial Sloan-Kettering Cancer Center in New York City, and colleagues prospectively classified 55 specimens harvested from RFA probes after liver treatment as coagulation necrosis and 13 as viable tumors. They found that these tissue samples could predict when RFA treatment would not be successful. Primary local tumor progression occurred in 92% of viable tumors versus 29% of those identified by post-RFA biopsy as necrotic. Investigators also found the long-term progression-free interval was about six times greater in the necrotic group. Both findings were statistically significant (p < 0.001).

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.